Gamma-hydroxybutyrate concentrations in the blood of impaired drivers, users of illicit drugs, and medical examiner cases

Journal of Analytical Toxicology

Volumn 31, Issue 9, 2007, Pages 566-572

  Jones, A Wayne ^a   Holmgren, Anita ^a   Kugelberg, Fredrik C ^a  

^a Department of Forensic Genetics and Forensic Toxicology   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYBUTYRIC ACID; GAMMA BUTYROLACTONE; GAMMA VALEROLACTONE; ILLICIT DRUG; LACTONE DERIVATIVE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGITATION; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRIVER; DRUG HALF LIFE; FEMALE; GAS CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; SEDATION; SLURRED SPEECH;

EID: 37349037839     PISSN: 01464760     EISSN: 01464760     Source Type: Journal    
DOI: 10.1093/jat/31.9.566     Document Type: Article

References (33)

1. A. Eklund. Gamma-hydroxybutyrate (GHB) - Endogena koncentrationer, missbruk, trafikolyckor och dödsfall. Nordisk Rettsmed. 7: 33-35 (2001).
2. K. Knudsen, J. Greter, M. Verdicchio, and T. Cederquist. GHB, GBL och butandiolförgiftningar - ett allvarligt problem i Västsverige. Läkartidningen. 102: 3294-3297 (2005).
3. E. Ohlin. Omöjiligt natkotikaklassa GBL och butandiol. Läkartidningen. 102: 3284-3285 (2005).
4. A.W. Jones. Driving under the influence of drugs in Sweden with zero concentration limits in blood for controlled substances. Traffic Inj. Prev. 6: 317-322 (2005).
5. A. Holmgren, P. Holmgren, F.C. Kugelberg, A.W. Jones, and J. Ahlner. Predominance of illicit drugs and polydrug use among drug impaired drivers in Sweden. Traffic Inj. Prev. 8: (2007).
6. A.W. Jones, A. Holmgren, and F.C. Kugelberg. Concentrations of scheduled prescription drugs in blood of impaired drivers: considerations for interpreting the results. Ther. Drug Monit. 29: 248-260 (2007).
7. A. Eklund, J. Jonsson, and J. Schuberth. A procedure for simultaneous screening and quantitation of basic drugs in liver, utilizing capillary gas chromatography and nitrogen sensitive detection. J. Anal. Toxicol. 7: 24-28 (1983).
8. R. Kronstrand and A.W. Jones. "Drugs of Abuse, analysis". In Encyclopedia of Forensic Sciences. J.A. Siegel, P.J. Saukko, and G.C. Knupfer, Eds. Academic Press, London, 2000, pp. 598-610.
9. S. Abanades, M. Farre, M. Segura, S. Pichini, D. Barral, R. Pacifici, M. Pellegrini, F. Fonseca, K. Langohr, and R. de la Torre. Gamma-hydroxybutyrate (GHB) in humans: pharmacodynamics and pharmacokinetics. Ann. N.Y. Acad. Sci. 1074: 559-576 (2006).
10. S. Abanades, M. Farre, M. Segura, S. Pichini, A. Pastor, R. Pacifici, M. Pellegrini, and R. de la Torre. Disposition of gamma-hydroxybutyrate in conventional and nonconventional biologic fluids after single drug administration: issues in methodology and drug monitoring. Ther. Drug Monit. 29: 64-70 (2007).
11. L.A. Borgen, R. Okerholm, D. Morrison, and A. Lai. The influence of gender and food on the pharmacokinetics of sodium oxybate oral solution in healthy subjects. J. Clin. Pharmacol. 43: 59-65 (2003).
12. L.A. Borgen, R. Okerholm, A. Lai, and M.B. Scharf. The pharmacokinetics of sodium oxybate oral solution following acute and chronic administration to narcoleptic patients. J. Clin. Pharmacol. 44: 253-257 (2004).
13. R. Brenneisen, M.A. Elsohly, T.P. Murphy, J. Passarelli, S. Russmann, S.J. Salamone, and D.E.Watson. Pharmacokinetics and excretion of gamma-hydroxybutyrate (GHB) in healthy subjects. J. Anal. Toxicol. 28: 625-630 (2004).
14. S.D. Ferrara, S. Zotti, L. Tedeschi, G. Frison, F. Castagna, L. Gallimberti, G.L. Gessa, and P. Palatini. Pharmacokinetics and gamma-hydroxybutyric acid in alcohol dependent patients after single and repeated oral doses. Br. J. Clin. Pharmacol. 34: 231-235 (1992).
15. S.D. Ferrara, L. Tedeschi, G. Frison, R. Orlando, M. Mazzo, R. Zordan, R. Padrini, and P. Palatini. Effect of moderate of severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid. Eur. J. Clin. Pharmacol. 50: 305-310 (1996).
16. P. Palatini, L. Tedeschi, G. Frison, R. Padrini, R. Zordan, R. Orlando, L. Gallimberti, G.L. Gessa, and S.D. Ferrara. Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers. Eur. J. Clin. Pharmacol. 45: 353-356 (1993).
17. D. Thai, D.E. Dyer, N.L. Benowitz, and C.A. Haller. Gamma-hydroxybutyrate and ethanol effects and interactions in humans. J. Clin. Psychopharmacol. 26: 524-529 (2006).
18. M.B. Scharf, A. Lai, B. Branigan, R. Stover, and D.B. Berkowitz. Pharmacokinetics of gammahydroxybutyrate (GHB) in narcoleptic patients. Sleep 21: 507-514 (1998).
19. K.R. Drasbek, J. Christensen, and K. Jensen. Gamma-hydroxybutyrate - a drug of abuse. Acta Neurol. Scand. 114: 145-156 (2006).
20. R. Iffland, A. West, N. Bilzer, and A. Schuff. Zur zuverlässigkeit der blutalkoholbestimmung. Das verteilungsverhältnis des wasserszwischen serum und vollblut. Rechtsmedizin. 9: 123-130 (1999).
21. A.W. Jones and D.J. Pounder. "Update on clinical and Forensic analysis". Drug Abuse Handbook. S.B. Karch, Ed. Taylor and Francis CRC Press, Boca Raton, FL, 2007, pp. 333-374.
22. A.W. Jones and K.Å. Jönsson. Food-induced lowering of blood-ethanol profiles and increased rate of elimination immediately after a meal. J. Forensic Sci. 39: 1084-1093 (1994).
23. F.J. Couper and B.K. Logan. GHB and driving impairment. J. Forensic Sci. 46: 919-923 (2001).
24. F.J. Couper and B.K. Logan. Addicted to driving under the influence - a GHB/GBL case report. J. Anal. Toxicol. 28: 512-515 (2004).
25. B.G. Stephens and R.C. Baselt. Driving under the influence of GHB? J. Anal. Toxicol. 18: 357-358 (1994).
26. A. Holmgren, P. Holmgren, F.C. Kugelberg, A.W. Jones, and J. Ahlner. High rearrest rates among drug impaired drivers despite zero-tolerance legislation. Accid. Anal. Prev. 40: in press.
27. U.S. Xyrem Multi-Center Study Group. The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms. J. Toxicol. Clin. Toxicol. 41: 131-135 (2003).
28. C.G. Wong, K.F. Chan, K.M. Gibson, and O.C. Snead. Gamma-hydroxybutyric acid: neurobiology and toxicology of a recreational drug. Toxicol. Rev. 23: 3-20 (2004).
29. R. Bernasconi, P. Mathivet, S. Bischoff, and C. Marescaux. Gamma-hydroxybutyric acid: an endogenous neuromodulator with abuse potential? Trends Pharmacol. Sci. 20: 135-141 (1999).
30. D.G. Caldicott, F.Y. Chow, B.J. Burns, P.D. Felgate, and R.W. Byard. Fatalities associated with the use of gamma-hydroxybutyrate and its analogues in Australasia. Med. J. Aust. 181: 310-313 (2004).
31. S.P. Elliott. Gamma hydroxybutyric acid (GHB) concentrations in humans and factors affecting endogenous production. J. Forensic Sci. 133: 9-15 (2003).
32. M.A. LeBeau, R.H. Christenson, B. Levine, W.D. Darwin, and M.A. Huestis. Intra- and interindividual variations in urinary concentrations of endogenous gamma-hydroxybutyrate. J. Anal. Toxicol. 26: 340-346 (2002).
33. M.A. LeBeau, M.A. Montgomery, C. Morris-Kukoski, J.E. Schaff, and A. Deakin. Further evidence of in vitro production of gamma-hydroxybutyrate (GHB) in urine samples. Forensic Sci. Int. 169: 152-156 (2006).